Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

949
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
949
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

659
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
659
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

330
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
330
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

344
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
344
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

7.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients.

Journal of lipid research·2026
Same author

Report on the Joint Symposium of the Korean Society of CardioMetabolic Syndrome (KSCMS) and the Japanese Society of Hypertension (JSH) at the 8th Asia-Pacific CardioMetabolic Syndrome (APCMS) Congress in Seoul.

Hypertension research : official journal of the Japanese Society of Hypertension·2025
Same author

Sex-specific impact of the COVID-19 outbreak on the incidence of metabolic syndrome: a comparative study of 2018-2019 and 2020-2021.

The Korean journal of internal medicine·2025
Same author

Cardiometabolic Diseases and Depression: Which Came First, the Chicken or the Egg?

JACC. Asia·2024
Same author

Metabolic syndrome awareness in the general Korean population: results from a nationwide survey.

The Korean journal of internal medicine·2024
Same author

Adiponectin and cardiometabolic trait and mortality: where do we go?

Cardiovascular research·2021

Related Experiment Video

Updated: Mar 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Intriguing Off-Target Effects of Ezetimibe

Kwang Kon Koh

    Journal of the American College of Cardiology
    |December 25, 2015
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.2K
    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
    08:18

    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

    Published on: January 7, 2019

    9.7K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    15.2K
    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.2K
    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
    08:18

    High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

    Published on: January 7, 2019

    9.7K